Medical Research News

Nursing

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bhargava A et al. – Satraplatin has a favorable toxicity profile, and appears to have clinical activity against a variety of malignancies such as breast, prostate and lung cancer. The oral route of administration and the intermittent schedule makes it very convenient for clinical use. Despite this, a FDA–approved indication has not yet been achieved. The only Phase III trial with satraplatin was conducted in pretreated metastatic castrate–resistant prostate cancer (CRPC), revealing an improvement in progression–free survival but no overall survival benefit. Future development would have to include designing trials in docetaxel–refractory metastatic CRPC, or in other malignancies where cisplatin is of benefit.

Today in Clinical Pharmacology...keeping you current

Clinical Features of Gastroduodenal Ulcer in Japanese Patients Taking Low-Dose Aspirin
Digestive Diseases and Sciences, 11/24/09

Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer
Case Reports in Gastroenterology, 11/24/09

Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy
Journal of Clinical Endocrinology and Metabolism, 11/24/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address